Joanne Smith-Farrell, Be Bio CEO
April 14, 2022 06:30 AM EDT
Financing
Startups
Cell/Gene Tx

ARCH leads $130M in­fu­sion in­to Be Bio's long pur­suit of B cell ther­a­pies for rare dis­ease, can­cer

Amber Tong

When Be Bio­phar­ma re­vealed it­self a year and a half ago with $52 mil­lion, the Long­wood-found­ed start­up was con­fi­dent about its vi­sion of cre­at­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times